On December 15, 2021 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ: NBI) and the iShares Biotechnology ETF (NYSE: IBB) (Press release, Curis, DEC 15, 2021, View Source [SID1234597191]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Nasdaq Biotechnology Index is a modified market capitalization-weighted index designed to track the performance of a set of qualifying NASDAQ-listed securities classified as either biotechnology or pharmaceuticals, according to the Industry Classification Benchmark. For more information about the Nasdaq Biotechnology Index visit www.nasdaq.com.

The iShares Biotechnology ETF is an exchange-traded fund designed to better represent the biotech industry by excluding pharmaceuticals, in favor of a modified market capitalization-weighted set of qualifying U.S.-listed biotechnology securities. For more information about the iShares Biotechnology ETF, visit www.ishares.com.

The additions will become effective prior to market open on Monday, December 20, 2021.